Barclays Maintains Overweight on Strategy, Raises Price Target to $175

Barclays analyst Nik Cremo has maintained an Overweight rating on Strategy (NASDAQ:MSTR) and increased the price target from $160 to $175. This adjustment reflects confidence in the company's strategic direction.